+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC)



Long-term results of the International Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small cell lung cancer (NSCLC)



Journal of Clinical Oncology 26(15_Suppl): 7507-7507



NlmCategory="UNASSIGNED">7507 Background: Based on 4 to 5-year follow-up data in recent randomized trials, adjuvant cisplatin-based chemotherapy is now generally recommended after complete surgical resection for patients with non-small-cell lung cancer. We evaluated the results of the IALT study, initially reported with a 4.7 year follow-up (ASCO 2003), with three additional years of follow-up. Patients with completely resected NSCLC were randomly assigned to three or four cycles of cisplatin-based chemotherapy or to observation. The dose of cisplatin (total 300-400 mg/m2), the drug to be combined with cisplatin (etoposide or vinorelbine or vindesine or vinblastin) and the use of adjuvant radiotherapy were predefined at each center. Cox models were used to evaluate treatment effect according to follow-up duration. Between February 1995 and December 2000, there were 1,867 patients included. Median follow-up was 7.5 years at the cut-off date of September 1, 2005. The survival status was known for 1,807 patients. Results showed a beneficial effect of adjuvant chemotherapy on overall survival (HR: 0.91; 95% CI: 0.81-1.02, p= 0.10) and on disease-free survival (HR: 0.88; 95% CI: 0.78-0.98, p= 0.02). However, there was a significant difference between the results of overall survival before and after 5 years (HR: 0.86; CI: 0.76-0.97, p = 0.01 versus HR: 1.45; CI: 1.02-2.07, p =0.04); p-value for interaction was 0.006. Disease-free survival benefit was also different according to the follow-up duration (p-value for interaction: 0.04; global, first 5 years, HR=0.85, p=0.006; after five year, HR=1.33, p=0.16). The analysis of non-lung cancer deaths for the whole period showed a HR of 1.34 (CI: 0.99-1.81; p=0.06). These results confirm the efficacy of chemotherapy for the first 5 years after surgery. The difference in results between less than and more than 5 years of follow-up may suggest possible late adjuvant chemotherapy-related over-mortality. This potential effect underscores the need for the long-term follow-up of adjuvant lung cancer trials in order to evaluate results in terms of treatment benefits and long-term hazards. [Table: see text].

(PDF emailed within 1 workday: $29.90)

Accession: 058235848

Download citation: RISBibTeXText

PMID: 27947281


Related references

Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. Journal of Clinical Oncology 28(1): 35-42, 2010

Impact of adjuvant chemotherapy (CT) on survival and local-control in non-small cell lung cancer (NSCLC): Results of the international adjuvant lung cancer trial (IALT). International Journal of Radiation Oncology*biology*physics 60: S239-S239, 2004

Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. Journal of Clinical Oncology 25(19): 2735-2740, 2007

Impact of histology on survival of resected non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy: subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation in the ANITA trial. Lung Cancer 74(1): 30-34, 2012

Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG). European Journal of Cardio-Thoracic Surgery 15(4): 438-443, 1999

Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clinical Cancer Research 13(13): 3892-3898, 2007

A randomized phase III trial of adjuvant chemotherapy with cisplatin and vindesine followed by UFT for completely resected pathologic (p-) stage IIIA-N2 non-small cell lung cancer (NSCLC): West Japan Study Group for Lung Cancer Surgery (WJSG) - the 5 th Study. Journal of Clinical Oncology 23(16_Suppl): 7262-7262, 2016

ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Journal of Clinical Oncology 23(16_Suppl): 7013-7013, 2016

Adjuvant chemotherapy improves overall and disease-free survival in non-small cell lung cancer Results of the randomized international adjuvant lung cancer Trial. EJC Suppl.s 1(5): S101, 2003

Feasibility trial for adjuvant chemotherapy with docetaxel plus cisplatin followed by single agent long-term administration of S-1 chemotherapy in patients with completely resected non-small cell lung cancer Thoracic Oncology Research Group Study 0809. British Journal of Cancer 109(3): 545-551, 2013

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA. Lung Cancer 82(1): 149-155, 2014

Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10. Journal of Clinical Oncology 23(16_Suppl): 7200-7200, 2016

Cisplatin-based adjuvant chemotherapy in resected non-small-cell lung cancer. Clinical Lung Cancer 5(1): 18-20, 2003

Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer. Clinical Cancer Research 21(23): 5245-5252, 2016

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet. Oncology 7(9): 719-727, 2006